Program
RAP-219
A development code.
Its studies are mostly in Seizures · Mania · Epilepsies, Partial, led by Rapport Therapeutics.
Furthest: phase 3, since Apr 16, 20265 company-led studies, 3 open or runningNext primary completion: Feb 3, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rapport Therapeutics | 53 open or running | phase 3since Apr 16, 2026 | Apr 17, 2024 | Feb 3, 2028phase 2 · NCT07219407 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2024First study: phase 2 study in SeizuresFirst studyNCT06377930 · 30 enrolled · United States
- May 30, 2025Phase 2 study in ManiaNCT07046494 · 253 enrolled · United States
- Oct 8, 2025Phase 2 study in Epilepsies, PartialNCT07219407 · 30 planned · United States
- Apr 16, 2026Phase 3 study in SeizuresPhase 3 reachedNCT07563881 · 333 planned · United States, Australia, South Korea and more
- May 11, 2026Phase 3 study in SeizuresNCT07594119 · 312 planned · United States, Australia, South Korea
Ahead
- Feb 3, 2028Primary completion: phase 2 study in Epilepsies, PartialNCT07219407
- Jul 2029Primary completion: phase 3 study in SeizuresNCT07594119
- Jul 2029Primary completion: phase 3 study in SeizuresNCT07563881
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07594119Seizures · United States, Australia, South Korea | 3 | Recruiting | Jul 2029 | 312 |
| NCT07563881Seizures · United States, Australia, South Korea and more | 3 | Recruiting | Jul 2029 | 333 |
| NCT07219407Epilepsies, Partial · United States | 2 | Recruiting | Feb 3, 2028 | 30 |
| NCT07046494Mania · United States | 2 | Completed | Aug 5, 2026 | 253 |
| NCT06377930Seizures · United States | 2 | Completed | Sep 26, 2025 | 30 |
How it is read
Names in the registry
- “RAP-219”, 7 entries
Codes read as this program: RAP219.
Conditions, from the studies’ own filings
- Seizures, 3 studies
- Mania, 1 study
- Epilepsies, Partial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.